Authors

Guenther Koehne, Miami Cancer InstituteFollow

Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

Publication Date

7-24-2024

Content Type

Article

PubMed ID:

39055646

Additional Authors:

Additional authors and institutional affiliations

Comments

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. © 2024

Citation

Tomasson, M. H., Iida, S., Niesvizky, R., Mohty, M., Bahlis, N. J., Martinez-Lopez, J., Koehne, G., Rodriguez-Otero, P., Miles Prince, H., Viqueira, A., Leip, E., Conte, U., Sullivan, S. T., & Lesokhin, A. M. (2024). Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study. HemaSphere, 8(7), e136. https://doi.org/10.1002/hem3.136